Swipe om te navigeren naar een ander artikel
Undetected heart failure appears to be an important health problem in patients with type 2 diabetes and aged ≥ 60 years. The prevalence of previously unknown heart failure in these patients is high, steeply rises with age, and is overall higher in women than in men. The majority of the patients with newly detected heart failure have a preserved ejection fraction. A diagnostic algorithm to detect or exclude heart failure in these patients with variables from the medical files combined with items from history taking and physical examination provides a good to excellent accuracy. Annual screening appears to be cost-effective. Both unrecognised heart failure with reduced and with preserved ejection fraction were associated with a clinically relevant lower health status in patients with type 2 diabetes. Also the prognosis of these patients was worse than of those without heart failure. Existing disease-management programs for type 2 diabetes pay insufficient attention to early detection of cardiovascular diseases, including heart failure. We conclude that more attention is needed for detection of heart failure in older patients with type 2 diabetes.
Boonman-de Winter LJ. Uncovering Heart Failure in Type 2 Diabetes. Utrecht: University Utrecht; 2015.
Wilson JM, Jungner YG. [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam. 1968;65:281–393. PubMed
McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–69. CrossRefPubMed
American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37(Suppl 1):S14–80. CrossRef
Rutten GEHM, De Grauw WJC, Nijpels G, et al. The NHG guideline Diabetes mellitus type 2. Huisarts Wet. 2013;56:512–25.
Wermeling PR, Gorter KJ, Stellato RK, de Wit GA, Beulens JW, Rutten GE. Effectiveness and cost-effectiveness of 3-monthly versus 6-monthly monitoring of well-controlled type 2 diabetes patients: a pragmatic randomised controlled patient-preference equivalence trial in primary care (EFFIMODI study). Diabetes Obes Metab. 2014;16:841–9. CrossRefPubMed
National Collaborating Centre for Chronic Conditions (UK). National clinical guideline for management in primary and secondary care (update) nice clinical guidelines, No. 66. London: Royal College of Physicians; 2008.
Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671–9. CrossRef
Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035–87. CrossRefPubMed
- Uncovering heart failure with preserved ejection fraction in patients with type 2 diabetes in primary care: time for a change
L. J. M. Boonman-de Winter
M. J. Cramer
A. W. Hoes
F. H. Rutten
- Bohn Stafleu van Loghum